Amoxicillin: Difference between revisions

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
imported>GreenC bot
 
imported>Tenshibeat
amoxycillin is no longer the AAN since 2020/2023
 
(2 intermediate revisions by 2 users not shown)
Line 4: Line 4:
{{cs1 config|mode=cs1 |name-list-style=vanc |display-authors=6}}
{{cs1 config|mode=cs1 |name-list-style=vanc |display-authors=6}}
{{Infobox drug
{{Infobox drug
| Watchedfields     = changed
| Watchedfields = changed
| verifiedrevid     = 455343638
| verifiedrevid = 455343638
| image             = Amoxicillin skeletal formula labelled.svg
| image = Amoxicillin skeletal formula labelled.svg
| image_class       = skin-invert-image
| image_class = skin-invert-image
| width             =
| width =  
| alt               =
| alt =  
| caption           =
| caption =  
| image2             = Amoxicillin-from-xtal-3D-bs-17.png
| image2 = Amoxicillin-from-xtal-3D-bs-17.png
| image_class2       = bg-transparent
| image_class2 = bg-transparent
| width2             =
| width2 =  
| alt2               =
| alt2 =  
| AAN                = Amoxycillin


<!-- Clinical data -->
<!-- Clinical data -->| pronounce = {{IPAc-en|ə|ˌ|m|ɒ|k|s|ᵻ|ˈ|s|ɪ|l|ᵻ|n}}
| pronounce         = {{IPAc-en|ə|ˌ|m|ɒ|k|s|ᵻ|ˈ|s|ɪ|l|ᵻ|n}}
| tradename = Amoxil, Trimox, others<ref name=brands/>
| tradename         = Amoxil, Trimox, others<ref name=brands/>
| Drugs.com = {{drugs.com|monograph|amoxicillin}}
| Drugs.com         = {{drugs.com|monograph|amoxicillin}}
| MedlinePlus = a685001
| MedlinePlus       = a685001
| DailyMedID = Amoxicillin
| DailyMedID         = Amoxicillin
| pregnancy_AU = A
| pregnancy_AU       = A
| pregnancy_AU_comment =  
| pregnancy_AU_comment =
| pregnancy_category =  
| pregnancy_category =
| routes_of_administration = [[Oral administration|By mouth]], [[Intravenous therapy|intravenous]] ([[Intravenous therapy#Bolus|bolus]]), [[intramuscular injection|intramuscular]]
| routes_of_administration = [[Oral administration|By mouth]], [[Intravenous therapy#Bolus)|IV]] (bolus), [[intramuscular injection]]
| class = [[β-Lactam]] [[antibiotic]]; [[Aminopenicillin]]
| class             = [[β-Lactam]] [[antibiotic]]; [[Aminopenicillin]]
| ATC_prefix = J01
| ATC_prefix         = J01
| ATC_suffix = CA04
| ATC_suffix         = CA04
| ATC_supplemental = {{ATCvet|G51|AA03}}
| ATC_supplemental   = {{ATCvet|G51|AA03}}


<!-- Legal status -->
<!-- Legal status -->| legal_AU = S4
| legal_AU           = S4
| legal_AU_comment =  
| legal_AU_comment   =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR           = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =  
| legal_BR_comment   =
| legal_CA = Rx-only
| legal_CA           = Rx-only
| legal_CA_comment =  
| legal_CA_comment   =
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE           = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =  
| legal_DE_comment   =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ           = <!-- Class A, B, C -->
| legal_NZ_comment =  
| legal_NZ_comment   =
| legal_UK = POM
| legal_UK           = POM
| legal_UK_comment = <ref name="Amoxil SmPC">{{cite web | title=Amoxil Vials for Injection 500mg - Summary of Product Characteristics (SmPC) | website=(emc) | date=4 November 2021 | url=https://www.medicines.org.uk/emc/product/94/smpc | access-date=8 October 2022 | archive-date=10 October 2022 | archive-url=https://web.archive.org/web/20221010025443/https://www.medicines.org.uk/emc/product/94/smpc }}</ref>
| legal_UK_comment   = <ref name="Amoxil SmPC">{{cite web | title=Amoxil Vials for Injection 500mg - Summary of Product Characteristics (SmPC) | website=(emc) | date=4 November 2021 | url=https://www.medicines.org.uk/emc/product/94/smpc | access-date=8 October 2022 | archive-date=10 October 2022 | archive-url=https://web.archive.org/web/20221010025443/https://www.medicines.org.uk/emc/product/94/smpc | url-status=dead }}</ref>
| legal_US = Rx-only
| legal_US           = Rx-only
| legal_US_comment = <ref name="Amoxil FDA label">{{cite web | title=Amoxil (amoxicillin) Capsules, Tablets, Chewable Tablets, and Powder for Oral Suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=49302 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035635/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=49302 | url-status=live | quote=Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported rarely.}}</ref><ref name="Amoxil FDA approval">{{cite web | title=Amoxil: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035630/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459 }}</ref><ref name="Trimox FDA approval">{{cite web | title=Trimox: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061885 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035630/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061885 }}</ref><ref name="Moxatag FDA label">{{cite web | title=Moxatag (amoxicillin extended-release) Tablets Initial U.S. Approval: 1974 | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=364489 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035633/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=364489 | url-status=live }}</ref>
| legal_US_comment   = <ref name="Amoxil FDA label">{{cite web | title=Amoxil (amoxicillin) Capsules, Tablets, Chewable Tablets, and Powder for Oral Suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=49302 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035635/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=49302 | url-status=live | quote=Central Nervous System: Reversible hyperactivity, agitation, anxiety, insomnia, confusion, convulsions, behavioral changes, and/or dizziness have been reported rarely.}}</ref><ref name="Amoxil FDA approval">{{cite web | title=Amoxil: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035630/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050459 | url-status=dead }}</ref><ref name="Trimox FDA approval">{{cite web | title=Trimox: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061885 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035630/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=061885 | url-status=dead }}</ref><ref name="Moxatag FDA label">{{cite web | title=Moxatag (amoxicillin extended-release) Tablets Initial U.S. Approval: 1974 | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=364489 | access-date=8 October 2022 | archive-date=9 October 2022 | archive-url=https://web.archive.org/web/20221009035633/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=364489 | url-status=live }}</ref>
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN           = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =  
| legal_UN_comment   =
| legal_status = Rx-only
| legal_status       = Rx-only


<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->| bioavailability = [[Oral administration|Oral]]: 60%<ref name="DrugBank">{{cite web | title=Amoxicillin: Uses, Interactions, Mechanism of Action | website=DrugBank Online | date=18 January 1974 | url=https://go.drugbank.com/drugs/DB01060 | access-date=5 November 2024}}</ref>
| bioavailability   = [[Oral administration|Oral]]: 60%<ref name="DrugBank">{{cite web | title=Amoxicillin: Uses, Interactions, Mechanism of Action | website=DrugBank Online | date=18 January 1974 | url=https://go.drugbank.com/drugs/DB01060 | access-date=5 November 2024}}</ref>
| protein_bound = 17%<ref name="DrugBank" />
| protein_bound     = 17%<ref name="DrugBank" />
| metabolism = [[Hydroxylation]], [[oxidative deamination]], [[aliphatic chain]] [[oxidation]], [[decarboxylation]], [[glucuronidation]]<ref name="DrugBank" />
| metabolism         = [[Hydroxylation]], [[oxidative deamination]], [[aliphatic chain]] [[oxidation]], [[decarboxylation]], [[glucuronidation]]<ref name="DrugBank" />
| metabolites = Seven<ref name="DrugBank" />
| metabolites       = Seven<ref name="DrugBank" />
| onset = ≤1.3–1.5{{nbsp}}hours ({{Abbrlink|T<sub>max</sub>|time to peak concentrations}})<ref name="DrugBank" />
| onset             = ≤1.3–1.5{{nbsp}}hours ({{Abbrlink|T<sub>max</sub>|time to peak concentrations}})<ref name="DrugBank" />
| elimination_half-life = 61.3{{nbsp}}minutes (~1{{nbsp}}hour)<ref name="DrugBank" />
| elimination_half-life = 61.3{{nbsp}}minutes (~1{{nbsp}}hour)<ref name="DrugBank" />
| duration_of_action =  
| duration_of_action =  
| excretion         = [[Urine]]: 70–78% (after 6{{nbsp}}hours)<ref name="DrugBank" />
| excretion = [[Urine]]: 70–78% (after 6{{nbsp}}hours)<ref name="DrugBank" />


<!-- Identifiers -->
<!-- Identifiers -->| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref     = {{cascite|correct|??}}
| CAS_number = 26787-78-0
| CAS_number         = 26787-78-0
| CAS_supplemental =  
| CAS_supplemental   =
| PubChem = 33613
| PubChem           = 33613
| IUPHAR_ligand =  
| IUPHAR_ligand     =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref       = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01060
| DrugBank           = DB01060
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID_Ref   = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 31006
| ChemSpiderID       = 31006
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII_Ref           = {{fdacite|correct|FDA}}
| UNII = 9EM05410Q9
| UNII               = 9EM05410Q9
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref           = {{keggcite|correct|kegg}}
| KEGG = D07452
| KEGG               = D07452
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI_Ref         = {{ebicite|correct|EBI}}
| ChEBI = 2676
| ChEBI             = 2676
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL_Ref         = {{ebicite|correct|EBI}}
| ChEMBL = 1082
| ChEMBL             = 1082
| NIAID_ChemDB =  
| NIAID_ChemDB       =
| PDB_ligand =  
| PDB_ligand         =
| synonyms = Amoxycillin, amox
| synonyms           = Amoxycillin, amox


<!-- Chemical and physical data -->
<!-- Chemical and physical data -->| IUPAC_name = (2''S'',5''R'',6''R''<nowiki>)-6-{[(2</nowiki>''R'')-2-Amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| IUPAC_name         = (2''S'',5''R'',6''R''<nowiki>)-6-{[(2</nowiki>''R'')-2-Amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
| C = 16
| C                 = 16
| H = 19
| H                 = 19
| N = 3
| N                 = 3
| O = 5
| O                 = 5
| S = 1
| S                 = 1
| SMILES = O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccc(O)cc1)N)[C@H]3SC2(C)C
| SMILES             = O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccc(O)cc1)N)[C@H]3SC2(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref       = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
| StdInChI           = 1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1
| StdInChI_comment =  
| StdInChI_comment   =
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey_Ref   = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LSQZJLSUYDQPKJ-NJBDSQKTSA-N
| StdInChIKey       = LSQZJLSUYDQPKJ-NJBDSQKTSA-N
| density = 1.6±0.1 <ref name="chemsrc">{{cite web|url=https://www.chemsrc.com/en/cas/26787-78-0_946616.html|title=Amoxicillin|website=www.chemsrc.com|access-date=8 May 2018|archive-date=19 May 2017|archive-url=https://web.archive.org/web/20170519221150/http://www.chemsrc.com/en/cas/26787-78-0_946616.html|url-status=live}}</ref>
| density           = 1.6±0.1 <ref name="chemsrc">{{cite web|url=https://www.chemsrc.com/en/cas/26787-78-0_946616.html|title=Amoxicillin|website=www.chemsrc.com|access-date=8 May 2018|archive-date=19 May 2017|archive-url=https://web.archive.org/web/20170519221150/http://www.chemsrc.com/en/cas/26787-78-0_946616.html|url-status=live}}</ref>
| density_notes =  
| density_notes     =
| melting_point =  
| melting_point     =
| melting_high =  
| melting_high       =
| melting_notes =  
| melting_notes     =
| boiling_point =  
| boiling_point     =
| boiling_notes =  
| boiling_notes     =
| solubility =  
| solubility         =
| sol_units =  
| sol_units         =
| specific_rotation =  
| specific_rotation =
}}
}}


Line 115: Line 109:


<!-- Society and culture -->
<!-- Society and culture -->
Amoxicillin was discovered in 1958 and came into medical use in 1972.<ref>{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=978-3-527-60749-5|page=490|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA490|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA490|archive-date=8 September 2017}}</ref><ref>{{cite book| vauthors = Roy J |title=An introduction to pharmaceutical sciences production, chemistry, techniques and technology|date=2012|publisher=Woodhead Pub.|location=Cambridge|isbn=978-1-908818-04-1|page=239|url=https://books.google.com/books?id=0IdmAgAAQBAJ&pg=PA239|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=0IdmAgAAQBAJ&pg=PA239|archive-date=8 September 2017}}</ref> Amoxil was approved for medical use in the United States in 1974,<ref name="Amoxil FDA approval" /><ref name="Trimox FDA approval" /> and in the United Kingdom in 1977.<ref name="Amoxil SmPC" /> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> It is one of the most commonly prescribed antibiotics in children.<ref>{{cite book| vauthors = Kelly D |title=Diseases of the liver and biliary system in children|date=2008|publisher=Wiley-Blackwell|location=Chichester, UK|isbn=978-1-4443-0054-3|page=217|edition=3|url=https://books.google.com/books?id=z7nO3OrNXckC&pg=PA217|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=z7nO3OrNXckC&pg=PA217|archive-date=8 September 2017}}</ref> Amoxicillin is available as a [[generic medication]].<ref name=AHFS2015/> In 2022, it was the 26th most commonly prescribed medication in the United States, with more than 20{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Amoxicillin Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Amoxicillin | access-date = 30 August 2024 }}</ref>
Amoxicillin was discovered in 1958 and came into medical use in 1972.<ref>{{cite book| vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=978-3-527-60749-5|page=490|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA490|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA490|archive-date=8 September 2017}}</ref><ref>{{cite book| vauthors = Roy J |title=An introduction to pharmaceutical sciences production, chemistry, techniques and technology|date=2012|publisher=Woodhead Pub.|location=Cambridge|isbn=978-1-908818-04-1|page=239|url=https://books.google.com/books?id=0IdmAgAAQBAJ&pg=PA239|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=0IdmAgAAQBAJ&pg=PA239|archive-date=8 September 2017}}</ref> Amoxil was approved for medical use in the United States in 1974,<ref name="Amoxil FDA approval" /><ref name="Trimox FDA approval" /> and in the United Kingdom in 1977.<ref name="Amoxil SmPC" /> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> It is one of the most commonly prescribed antibiotics in children.<ref>{{cite book| vauthors = Kelly D |title=Diseases of the liver and biliary system in children|date=2008|publisher=Wiley-Blackwell|location=Chichester, UK|isbn=978-1-4443-0054-3|page=217|edition=3|url=https://books.google.com/books?id=z7nO3OrNXckC&pg=PA217|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://books.google.com/books?id=z7nO3OrNXckC&pg=PA217|archive-date=8 September 2017}}</ref> Amoxicillin is available as a [[generic medication]].<ref name=AHFS2015/> In 2023, it was the 23rd most commonly prescribed medication in the United States, with more than 23{{nbsp}}million prescriptions.<ref name="Top300Drugs">{{cite web | title=Top 300 of 2023 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=12 August 2025 | archive-date=12 August 2025 | archive-url=https://web.archive.org/web/20250812130026/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Amoxicillin Drug Usage Statistics, United States, 2014 - 2023 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Amoxicillin | access-date = 12 August 2025 }}</ref>


==Medical uses ==
==Medical uses ==
Line 122: Line 116:


===Acute otitis media===
===Acute otitis media===
Children with acute otitis media who are younger than six months of age are generally treated with amoxicillin or other antibiotics. Although most children with acute otitis media who are older than two years old do not benefit from treatment with amoxicillin or other antibiotics, such treatment may be helpful in children younger than two years old with acute otitis media that is bilateral or accompanied by ear drainage.<ref>{{cite journal | vauthors = Venekamp RP, Sanders SL, Glasziou PP, Rovers MM | title = Antibiotics for acute otitis media in children | journal = The Cochrane Database of Systematic Reviews | volume = 11 | issue = 11 | pages = CD000219 | date = November 2023 | pmid = 37965923 | pmc = 10646935 | doi = 10.1002/14651858.CD000219.pub5 }}</ref> In the past, amoxicillin was dosed three times daily when used to treat acute otitis media, which resulted in missed doses in routine [[Ambulatory care|ambulatory practice]]. There is now evidence that two-times daily dosing or once-daily dosing has similar effectiveness.<ref>{{cite journal | vauthors = Thanaviratananich S, Laopaiboon M, Vatanasapt P | title = Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media | journal = The Cochrane Database of Systematic Reviews | issue = 12 | pages = CD004975 | date = December 2013 | volume = 2014 | pmid = 24338106 | doi = 10.1002/14651858.CD004975.pub3 | pmc = 10960641 }}</ref>
Children with acute otitis media who are younger than six months of age are generally treated with amoxicillin or other antibiotics. Although most children with acute otitis media who are older than two years old do not benefit from treatment with amoxicillin or other antibiotics, such treatment may be helpful in children younger than two years old with acute otitis media that is bilateral or accompanied by ear drainage.<ref>{{cite journal | vauthors = Venekamp RP, Sanders SL, Glasziou PP, Rovers MM | title = Antibiotics for acute otitis media in children | journal = The Cochrane Database of Systematic Reviews | volume = 11 | issue = 11 | article-number = CD000219 | date = November 2023 | pmid = 37965923 | pmc = 10646935 | doi = 10.1002/14651858.CD000219.pub5 }}</ref> In the past, amoxicillin was dosed three times daily when used to treat acute otitis media, which resulted in missed doses in routine [[Ambulatory care|ambulatory practice]]. There is now evidence that two-times daily dosing or once-daily dosing has similar effectiveness.<ref>{{cite journal | vauthors = Thanaviratananich S, Laopaiboon M, Vatanasapt P | title = Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media | journal = The Cochrane Database of Systematic Reviews | issue = 12 | article-number = CD004975 | date = December 2013 | volume = 2014 | pmid = 24338106 | doi = 10.1002/14651858.CD004975.pub3 | pmc = 10960641 }}</ref>


===Respiratory infections===
===Respiratory infections===
Most sinusitis infections are caused by [[virus]]es, for which amoxicillin and amoxicillin-clavulanate are ineffective,<ref name="AAAAIfive">{{cite journal |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Allergy, Asthma, and Immunology]] |journal = Choosing Wisely: An Initiative of the ABIM Foundation |url = http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AAAAI.pdf |access-date = 14 August 2012 |url-status = live |archive-url = https://web.archive.org/web/20121103151124/http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AAAAI.pdf |archive-date = 3 November 2012 }}</ref> and the small benefit gained by amoxicillin may be overridden by the adverse effects.<ref name="antibioticssinusitis">{{cite journal | vauthors = Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW, Mäkelä M | title = Antibiotics for acute maxillary sinusitis in adults | journal = The Cochrane Database of Systematic Reviews | issue = 2 | pages = CD000243 | date = February 2014 | pmid = 24515610 | doi = 10.1002/14651858.CD000243.pub3 | veditors = Ahovuo-Saloranta A }}</ref>
Most sinusitis infections are caused by [[virus]]es, for which amoxicillin and amoxicillin-clavulanate are ineffective,<ref name="AAAAIfive">{{cite journal |title = Five Things Physicians and Patients Should Question |publisher = [[American Academy of Allergy, Asthma, and Immunology]] |journal = Choosing Wisely: An Initiative of the ABIM Foundation |url = http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AAAAI.pdf |access-date = 14 August 2012 |url-status = live |archive-url = https://web.archive.org/web/20121103151124/http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_AAAAI.pdf |archive-date = 3 November 2012 }}</ref> and the small benefit gained by amoxicillin may be overridden by the adverse effects.<ref name="antibioticssinusitis">{{cite journal | vauthors = Ahovuo-Saloranta A, Rautakorpi UM, Borisenko OV, Liira H, Williams JW, Mäkelä M | title = Antibiotics for acute maxillary sinusitis in adults | journal = The Cochrane Database of Systematic Reviews | issue = 2 | article-number = CD000243 | date = February 2014 | pmid = 24515610 | doi = 10.1002/14651858.CD000243.pub3 | veditors = Ahovuo-Saloranta A }}</ref>
Amoxicillin is considered the first-line [[empirical treatment]] for most cases of uncomplicated bacterial sinusitis in children and adults when culture data is unavailable.<ref>{{cite web | vauthors = Patel ZM, Peter HH |title=Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment |url=https://www.uptodate.com/contents/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment |url-status=live |archive-url=https://web.archive.org/web/20230313015138/https://www.uptodate.com/contents/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment |archive-date=13 March 2023 |access-date=13 November 2023 |website=[[UpToDate]]}}</ref><ref>{{cite Q|Q38897648}}</ref><ref>{{cite Q|Q104102440}}</ref> Amoxicillin is recommended as the preferred first-line treatment for [[community-acquired pneumonia]] in adults by the [[National Institute for Health and Care Excellence]], either alone (mild to moderate severity disease) or in combination with a [[macrolide]].<ref>{{cite book|url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071334/|title=Pneumonia: Diagnosis and Management of Community– and Hospital-Acquired Pneumonia in Adults |url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071334/|archive-date=8 September 2017|publisher=National Institute for Health and Care Excellence (UK)|year=2014|series=National Institute for Health and Care Excellence: Clinical Guidelines, No. 191 |pmid=25520986 |author1=National Clinical Guideline Centre (UK) }}</ref> Research suggests that is as effective as [[Amoxicillin/clavulanic acid|co-amoxiclav]] (a broad-spectrum antibiotic) for people admitted to hospital with pneumonia, regardless of its severity.<ref>{{cite journal | vauthors = Wei J, Uppal A, Nganjimi C, Warr H, Ibrahim Y, Gu Q, Yuan H, Rahman NM, Jones N, Walker AS, Eyre DW | title = No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia | language = English | journal = The Journal of Infection | volume = 88 | issue = 6 | pages = 106161 | date = June 2024 | pmid = 38663754 | doi = 10.1016/j.jinf.2024.106161 }}</ref><ref>{{Cite journal |date=22 November 2024 |title=Amoxicillin is effective for many people hospitalised with pneumonia |url=https://evidence.nihr.ac.uk/alert/amoxicillin-is-effective-for-many-people-hospitalised-with-pneumonia/ |journal=NIHR Evidence}}</ref> The [[World Health Organization]] (WHO) recommends amoxicillin as first-line treatment for pneumonia that is not "severe".<ref>{{cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK264162/|title=Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities - NCBI Bookshelf|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://www.ncbi.nlm.nih.gov/books/NBK264162/|archive-date=8 September 2017|isbn=978-92-4-150781-3|publisher=World Health Organization|year=2014|series=WHO Guidelines Approved by the Guidelines Review Committee|pmid=25535631 }}</ref> Amoxicillin is used in post-exposure inhalation of [[anthrax]] to prevent disease progression and for prophylaxis.<ref name = Davisamox/>
Amoxicillin is considered the first-line [[empirical treatment]] for most cases of uncomplicated bacterial sinusitis in children and adults when culture data is unavailable.<ref>{{cite web | vauthors = Patel ZM, Peter HH |title=Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment |url=https://www.uptodate.com/contents/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment |url-status=live |archive-url=https://web.archive.org/web/20230313015138/https://www.uptodate.com/contents/uncomplicated-acute-sinusitis-and-rhinosinusitis-in-adults-treatment |archive-date=13 March 2023 |access-date=13 November 2023 |website=[[UpToDate]]}}</ref><ref>{{cite Q|Q38897648}}</ref><ref>{{cite Q|Q104102440}}</ref> Amoxicillin is recommended as the preferred first-line treatment for [[community-acquired pneumonia]] in adults by the [[National Institute for Health and Care Excellence]], either alone (mild to moderate severity disease) or in combination with a [[macrolide]].<ref>{{cite book|url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071334/|title=Pneumonia: Diagnosis and Management of Community– and Hospital-Acquired Pneumonia in Adults |archive-url=https://web.archive.org/web/20170908135935/https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071334/|archive-date=8 September 2017|publisher=National Institute for Health and Care Excellence (UK)|year=2014|series=National Institute for Health and Care Excellence: Clinical Guidelines, No. 191 |pmid=25520986 |author1=National Clinical Guideline Centre (UK) }}</ref> Research suggests that is as effective as [[Amoxicillin/clavulanic acid|co-amoxiclav]] (a broad-spectrum antibiotic) for people admitted to hospital with pneumonia, regardless of its severity.<ref>{{cite journal | vauthors = Wei J, Uppal A, Nganjimi C, Warr H, Ibrahim Y, Gu Q, Yuan H, Rahman NM, Jones N, Walker AS, Eyre DW | title = No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia | language = English | journal = The Journal of Infection | volume = 88 | issue = 6 | article-number = 106161 | date = June 2024 | pmid = 38663754 | doi = 10.1016/j.jinf.2024.106161 | pmc = 11893475 }}</ref><ref>{{Cite journal |date=22 November 2024 |title=Amoxicillin is effective for many people hospitalised with pneumonia |url=https://evidence.nihr.ac.uk/alert/amoxicillin-is-effective-for-many-people-hospitalised-with-pneumonia/ |journal=NIHR Evidence}}</ref> The [[World Health Organization]] (WHO) recommends amoxicillin as first-line treatment for pneumonia that is not "severe".<ref>{{cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK264162/|title=Revised WHO Classification and Treatment of Pneumonia in Children at Health Facilities - NCBI Bookshelf|url-status=live|archive-url=https://web.archive.org/web/20170908135935/https://www.ncbi.nlm.nih.gov/books/NBK264162/|archive-date=8 September 2017|isbn=978-92-4-150781-3|publisher=World Health Organization|year=2014|series=WHO Guidelines Approved by the Guidelines Review Committee|pmid=25535631 }}</ref> Amoxicillin is used in post-exposure inhalation of [[anthrax]] to prevent disease progression and for prophylaxis.<ref name = Davisamox/>


===''H. pylori''===
===''H. pylori''===
It is effective as one part of a multi-drug regimen for the treatment of stomach infections of ''[[Helicobacter pylori]]''. It is typically combined with a [[proton-pump inhibitor]] (such as [[omeprazole]]) and a [[macrolide antibiotic]] (such as [[clarithromycin]]); other drug combinations are also effective.<ref>{{cite journal | vauthors = Chey WD, Leontiadis GI, Howden CW, Moss SF | title = ACG Clinical Guideline: Treatment of Helicobacter pylori Infection | journal = The American Journal of Gastroenterology | volume = 112 | issue = 2 | pages = 212–239 | date = February 2017 | pmid = 28071659 | doi = 10.1038/ajg.2016.563 | s2cid = 9390953 }}</ref>
It is effective as one part of a multi-drug regimen for the treatment of stomach infections of ''[[Helicobacter pylori]]''. It is typically combined with a [[proton-pump inhibitor]] (such as [[omeprazole]]) and a [[macrolide antibiotic]] (such as [[clarithromycin]]); other drug combinations are also effective.<ref>{{cite journal | vauthors = Chey WD, Leontiadis GI, Howden CW, Moss SF | title = ACG Clinical Guideline: Treatment of Helicobacter pylori Infection | journal = The American Journal of Gastroenterology | volume = 112 | issue = 2 | pages = 212–239 | date = February 2017 | pmid = 28071659 | doi = 10.1038/ajg.2016.563 | s2cid = 9390953 }}</ref>
One old article suggests using amoxicillin with [[bismuth subsalicylate]] (pepto bismol) which does work.<ref>{{cite journal | title=Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial | journal=PLOS ONE | date=2018 | volume=13 | issue=6 | article-number=e0197096 | doi=10.1371/journal.pone.0197096 | doi-access=free | pmid=29889843 | pmc=5995362 | vauthors = Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P | bibcode=2018PLoSO..1397096S }}</ref>


===Lyme borreliosis===
===Lyme borreliosis===
Line 135: Line 130:


===Odontogenic infections===
===Odontogenic infections===
Amoxicillin is used to treat [[odontogenic infections]], infections of the tongue, lips, and other oral tissues. It may be prescribed following a [[tooth extraction]], particularly in those with [[compromised immune system]]s.<ref>{{cite journal | vauthors = Tancawan AL, Pato MN, Abidin KZ, Asari AS, Thong TX, Kochhar P, Muganurmath C, Twynholm M, Barker K | title = Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin | journal = International Journal of Dentistry | volume = 2015 | pages = 472470 | date = 2015 | pmid = 26300919 | pmc = 4537712 | doi = 10.1155/2015/472470 | doi-access = free }}</ref>
Amoxicillin is used to treat [[odontogenic infections]], infections of the tongue, lips, and other oral tissues. It may be prescribed following a [[tooth extraction]], particularly in those with [[compromised immune system]]s.<ref>{{cite journal | vauthors = Tancawan AL, Pato MN, Abidin KZ, Asari AS, Thong TX, Kochhar P, Muganurmath C, Twynholm M, Barker K | title = Amoxicillin/Clavulanic Acid for the Treatment of Odontogenic Infections: A Randomised Study Comparing Efficacy and Tolerability versus Clindamycin | journal = International Journal of Dentistry | volume = 2015 | article-number = 472470 | date = 2015 | pmid = 26300919 | pmc = 4537712 | doi = 10.1155/2015/472470 | doi-access = free }}</ref>


===Skin infections===
===Skin infections===
Amoxicillin is occasionally used for the treatment of skin infections,<ref name = Davisamox/> such as [[acne vulgaris]].<ref>{{cite web | title = Adolescent Acne: Management | url = http://www.medscape.com/viewarticle/430534_5 | url-status = live | archive-url = https://web.archive.org/web/20101222205124/http://www.medscape.com/viewarticle/430534_5 | archive-date = 22 December 2010 }}</ref> It is often an effective treatment for cases of acne vulgaris that have responded poorly to other antibiotics, such as [[doxycycline]] and [[minocycline]].<ref>{{cite web |url=http://scienceofacne.com/amoxicillin/ |title=Amoxicillin and Acne Vulgaris |publisher=scienceofacne.com |date=5 September 2012 |access-date=17 August 2012 |url-status=dead |archive-url=https://web.archive.org/web/20120721002339/http://scienceofacne.com/amoxicillin/ |archive-date=21 July 2012 }}</ref>
Amoxicillin is occasionally used for the treatment of skin infections,<ref name = Davisamox/> such as [[acne vulgaris]].<ref>{{cite web | title = Adolescent Acne: Management | url = http://www.medscape.com/viewarticle/430534_5 | url-status = live | archive-url = https://web.archive.org/web/20101222205124/http://www.medscape.com/viewarticle/430534_5 | archive-date = 22 December 2010 }}</ref> It is often an effective treatment for cases of acne vulgaris that have responded poorly to other antibiotics, such as [[doxycycline]] and [[minocycline]].<ref>{{cite web |url=http://scienceofacne.com/amoxicillin/ |title=Amoxicillin and Acne Vulgaris |publisher=scienceofacne.com |date=5 September 2012 |access-date=17 August 2012 |archive-url=https://web.archive.org/web/20120721002339/http://scienceofacne.com/amoxicillin/ |archive-date=21 July 2012 }}</ref>


===Infections in infants in resource-limited settings===
===Infections in infants in resource-limited settings===
Line 144: Line 139:


===Prevention of bacterial endocarditis===
===Prevention of bacterial endocarditis===
It is also used to prevent [[bacterial endocarditis]] and as a pain-reliever in high-risk people having dental work done, to prevent ''[[Streptococcus pneumoniae]]'' and other [[encapsulated bacteria]]l infections in those without [[spleen]]s, such as people with [[sickle-cell disease]], and for both the prevention and the treatment of [[anthrax]].<ref name=AHFS2015/> The United Kingdom recommends against its use for infectious endocarditis prophylaxis.<ref>{{cite web|title=CG64 Prophylaxis against infective endocarditis: Full guidance |url=http://www.nice.org.uk/nicemedia/live/11938/40039/40039.pdf |work=NICE |access-date=8 June 2011 |url-status=dead |archive-url=https://web.archive.org/web/20111112000314/http://www.nice.org.uk/nicemedia/live/11938/40039/40039.pdf |archive-date=12 November 2011 }}</ref> These recommendations do not appear to have changed the rates of infection for infectious endocarditis.<ref>{{cite journal | vauthors = Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, Lockhart PB | title = Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study | journal = BMJ | volume = 342 | pages = d2392 | date = May 2011 | pmid = 21540258 | pmc = 3086390 | doi = 10.1136/bmj.d2392 }}</ref>
It is also used to prevent [[bacterial endocarditis]] and as a pain-reliever in high-risk people having dental work done, to prevent ''[[Streptococcus pneumoniae]]'' and other [[encapsulated bacteria]]l infections in those without [[spleen]]s, people with damaged spleens (such as some with [[sickle-cell disease]]), and for both the prevention and the treatment of [[anthrax]].<ref name=AHFS2015/> The United Kingdom recommends against its use for infectious endocarditis prophylaxis.<ref>{{cite web|title=CG64 Prophylaxis against infective endocarditis: Full guidance |url=http://www.nice.org.uk/nicemedia/live/11938/40039/40039.pdf |work=NICE |access-date=8 June 2011 |archive-url=https://web.archive.org/web/20111112000314/http://www.nice.org.uk/nicemedia/live/11938/40039/40039.pdf |archive-date=12 November 2011 }}</ref> These recommendations do not appear to have changed the rates of infection for infectious endocarditis.<ref>{{cite journal | vauthors = Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, Lockhart PB | title = Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study | journal = BMJ | volume = 342 | article-number = d2392 | date = May 2011 | pmid = 21540258 | pmc = 3086390 | doi = 10.1136/bmj.d2392 }}</ref>


===Combination treatment===
===Combination treatment===
{{Main|Amoxicillin/clavulanic acid}}
{{Main|Amoxicillin/clavulanic acid}}


Amoxicillin is susceptible to degradation by [[beta-lactamase|β-lactamase]]-producing bacteria, which are resistant to most β-lactam antibiotics, such as [[penicillin]]. For this reason, it may be combined with [[clavulanic acid]], a [[β-lactamase inhibitor]]. This drug combination is commonly called [[Coamoxiclav|co-amoxiclav]].<ref>{{cite web|title=Amoxicillin Susceptibility and Resistance Data|url=http://www.toku-e.com/Assets/MIC/AmoxicillinClavulanate%20augmentin.pdf|access-date=20 July 2013|archive-url=https://web.archive.org/web/20190713141750/http://www.toku-e.com/Assets/MIC/AmoxicillinClavulanate%20augmentin.pdf|archive-date=13 July 2019|url-status=dead}}</ref>
Amoxicillin is susceptible to degradation by [[beta-lactamase|β-lactamase]]-producing bacteria, which are resistant to most β-lactam antibiotics, such as [[penicillin]]. For this reason, it may be combined with [[clavulanic acid]], a [[β-lactamase inhibitor]]. This drug combination is commonly called [[Coamoxiclav|co-amoxiclav]].<ref>{{cite web|title=Amoxicillin Susceptibility and Resistance Data|url=http://www.toku-e.com/Assets/MIC/AmoxicillinClavulanate%20augmentin.pdf|access-date=20 July 2013|archive-url=https://web.archive.org/web/20190713141750/http://www.toku-e.com/Assets/MIC/AmoxicillinClavulanate%20augmentin.pdf|archive-date=13 July 2019}}</ref>


=== Spectrum of activity ===
=== Spectrum of activity ===


It is a [[Antimicrobial spectrum|moderate-spectrum]], [[bacteriolytic]], [[β-lactam antibiotic]] in the [[aminopenicillin]] family used to treat susceptible [[Gram-positive]] and [[Gram-negative]] bacteria. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other β-lactam antibiotics.
It is a [[Antimicrobial spectrum|moderate-spectrum]], [[bacteriolytic]], [[β-lactam antibiotic]] in the [[aminopenicillin]] family used to treat susceptible [[Gram-positive]] and [[Gram-negative]] bacteria. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other β-lactam antibiotics.
In general, ''[[Streptococcus]], [[Bacillus subtilis]], [[Enterococcus]], [[Haemophilus]], [[Helicobacter]],'' and ''[[Moraxella]]'' are susceptible to amoxicillin, whereas ''[[Citrobacter]], [[Klebsiella]]'' and ''[[Pseudomonas aeruginosa]]'' are resistant to it.<ref>{{cite web|title=Amoxicillin spectrum of bacterial susceptibility and Resistance|url=http://www.toku-e.com/Assets/MIC/Amoxicillin%20sodium%20salt.pdf|access-date=8 April 2012|archive-url=https://web.archive.org/web/20181222141136/http://www.toku-e.com/Assets/MIC/Amoxicillin%20sodium%20salt.pdf|archive-date=22 December 2018|url-status=dead}}</ref> Some ''[[Escherichia coli|E. coli]]'' and most clinical strains of ''[[Staphylococcus aureus]]'' have developed resistance to amoxicillin to varying degrees.<ref>{{cite journal | vauthors = Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, Dittrich S | title = Antimicrobial resistance in Africa: a systematic review | journal = BMC Infectious Diseases | volume = 17 | issue = 1 | pages = 616 | date = September 2017 | pmid = 28893183 | pmc = 5594539 | doi = 10.1186/s12879-017-2713-1 | doi-access = free }}</ref>
In general, ''[[Streptococcus]], [[Bacillus subtilis]], [[Enterococcus]], [[Haemophilus]], [[Helicobacter]],'' and ''[[Moraxella]]'' are susceptible to amoxicillin, whereas ''[[Citrobacter]], [[Klebsiella]]'' and ''[[Pseudomonas aeruginosa]]'' are resistant to it.<ref>{{cite web|title=Amoxicillin spectrum of bacterial susceptibility and Resistance|url=http://www.toku-e.com/Assets/MIC/Amoxicillin%20sodium%20salt.pdf|access-date=8 April 2012|archive-url=https://web.archive.org/web/20181222141136/http://www.toku-e.com/Assets/MIC/Amoxicillin%20sodium%20salt.pdf|archive-date=22 December 2018}}</ref> Some ''[[Escherichia coli|E. coli]]'' and most clinical strains of ''[[Staphylococcus aureus]]'' have developed resistance to amoxicillin to varying degrees.<ref>{{cite journal | vauthors = Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, Dittrich S | title = Antimicrobial resistance in Africa: a systematic review | journal = BMC Infectious Diseases | volume = 17 | issue = 1 | article-number = 616 | date = September 2017 | pmid = 28893183 | pmc = 5594539 | doi = 10.1186/s12879-017-2713-1 | doi-access = free }}</ref>


==Adverse effects==
==Adverse effects==
[[Adverse drug reaction|Adverse effect]]s are similar to those for other [[β-lactam antibiotic]]s, including [[nausea]], [[vomiting]], [[rash]]es, and antibiotic-associated [[colitis]]. [[Diarrhea]] (loose bowel movements) may also occur.
[[Adverse drug reaction|Adverse effect]]s are similar to those for other [[β-lactam antibiotic]]s, including [[nausea]], [[vomiting]], [[rash]]es, and antibiotic-associated [[colitis]]. [[Diarrhea]] (loose bowel movements) may also occur.


Rarer adverse effects include mental and behavioral changes, [[lightheadedness]], [[insomnia]], [[hyperactivity]], [[psychomotor agitation|agitation]], [[mental confusion|confusion]], [[anxiety]], [[sensory overload|sensitivity to lights and sounds]], and [[cognitive impairment|unclear thinking]].<ref name="Amoxil FDA label" /><ref name="EspositoCaneviniPrincipi2017">{{cite journal | vauthors = Esposito S, Canevini MP, Principi N | title = Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs | journal = Int J Antimicrob Agents | volume = 50 | issue = 1 | pages = 1–8 | date = July 2017 | pmid = 28414069 | doi = 10.1016/j.ijantimicag.2017.01.027 | url = | quote = Benzylpenicillin, the most neurotoxic among the penicillins, has often been associated with the development of encephalopathy and seizures both in animals and humans [21], [22]. However, some neurological adverse effects (anxiety, hyperactivity, confusion, convulsions, and behavioural changes) have also been reported for amoxicillin and ampicillin, the two penicillins with the lowest risk of neurotoxicity [22], [23], [24], [25], [26], [27]. Moreover, ampicillin may cause seizures when administered to very low-birth-weight neonates [28].}}</ref><ref name="JangLeeJang2018">{{cite journal | vauthors = Jang HM, Lee HJ, Jang SE, Han MJ, Kim DH | title = Evidence for interplay among antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in mice | journal = Mucosal Immunol | volume = 11 | issue = 5 | pages = 1386–1397 | date = September 2018 | pmid = 29867078 | doi = 10.1038/s41385-018-0042-3 | url = | quote = However, treatment with amoxicillin has been reported to cause adverse neurological effects such as anxiety, hyperactivity, confusion, and behavioral changes as side effects in children.21}}</ref> Immediate medical care is required upon the first signs of these adverse effects.<ref name="AHFS2015" /> Similarly to other penicillins, amoxicillin has been associated with an increased risk of [[seizure]]s.<ref name="Amoxil FDA label" /><ref name="EspositoCaneviniPrincipi2017" /><ref name="NestorRyanCook2010">{{cite journal | vauthors = Nestor MA, Ryan M, Cook AM | title = Catching the seizure culprit: drugs on the differential | journal = Orthopedics | volume = 33 | issue = 9 | pages = 679–682 | date = September 2010 | pmid = 20839747 | doi = 10.3928/01477447-20100722-16 | url = | quote = }}</ref><ref name="AtliDemir-OzkayIlgin2016">{{cite journal | vauthors = Atli O, Demir-Ozkay U, Ilgin S, Aydin TH, Akbulut EN, Sener E | title = Evidence for neurotoxicity associated with amoxicillin in juvenile rats | journal = Hum Exp Toxicol | volume = 35 | issue = 8 | pages = 866–876 | date = August 2016 | pmid = 26429924 | doi = 10.1177/0960327115607948 | bibcode = 2016HETox..35..866A | url = | quote = Till date, limited number of acute psychiatric adverse events (including seizure, encephalopathy, and tremor) related to AMX treatment have been reported in patients with no underlying psychiatric disorders.11–15 Furthermore, the Food and Drug Administration has published a report that when AMX was coadministered with cephalosporin, this combination therapy might cause death by inducing seizures in a patient.16}}</ref> Amoxicillin-induced [[neurotoxicity]] has been especially associated with concentrations of greater than 110{{nbsp}}mg/L.<ref name="LalanneBouzilléTron2023">{{cite journal | vauthors = Lalanne S, Bouzillé G, Tron C, Revest M, Polard E, Bellissant E, Verdier MC, Lemaitre F | title = Amoxicillin-Induced Neurotoxicity: Contribution of a Healthcare Data Warehouse to the Determination of a Toxic Concentration Threshold | journal = Antibiotics | volume = 12 | issue = 4 | date = March 2023 | page = 680 | pmid = 37107042 | pmc = 10135267 | doi = 10.3390/antibiotics12040680 | doi-access = free | url = }}</ref>
Rarer adverse effects include mental and behavioral changes, [[lightheadedness]], [[insomnia]], [[hyperactivity]], [[psychomotor agitation|agitation]], [[mental confusion|confusion]], [[anxiety]], [[sensory overload|sensitivity to lights and sounds]], and [[cognitive impairment|unclear thinking]].<ref name="Amoxil FDA label" /><ref name="EspositoCaneviniPrincipi2017">{{cite journal | vauthors = Esposito S, Canevini MP, Principi N | title = Complications associated with antibiotic administration: neurological adverse events and interference with antiepileptic drugs | journal = Int J Antimicrob Agents | volume = 50 | issue = 1 | pages = 1–8 | date = July 2017 | pmid = 28414069 | doi = 10.1016/j.ijantimicag.2017.01.027 | url = | quote = Benzylpenicillin, the most neurotoxic among the penicillins, has often been associated with the development of encephalopathy and seizures both in animals and humans [21], [22]. However, some neurological adverse effects (anxiety, hyperactivity, confusion, convulsions, and behavioural changes) have also been reported for amoxicillin and ampicillin, the two penicillins with the lowest risk of neurotoxicity [22], [23], [24], [25], [26], [27]. Moreover, ampicillin may cause seizures when administered to very low-birth-weight neonates [28].}}</ref><ref name="JangLeeJang2018">{{cite journal | vauthors = Jang HM, Lee HJ, Jang SE, Han MJ, Kim DH | title = Evidence for interplay among antibacterial-induced gut microbiota disturbance, neuro-inflammation, and anxiety in mice | journal = Mucosal Immunol | volume = 11 | issue = 5 | pages = 1386–1397 | date = September 2018 | pmid = 29867078 | doi = 10.1038/s41385-018-0042-3 | url = | quote = However, treatment with amoxicillin has been reported to cause adverse neurological effects such as anxiety, hyperactivity, confusion, and behavioral changes as side effects in children.21| doi-access = free }}</ref> Immediate medical care is required upon the first signs of these adverse effects.<ref name="AHFS2015" /> Similarly to other penicillins, amoxicillin has been associated with an increased risk of [[seizure]]s.<ref name="Amoxil FDA label" /><ref name="EspositoCaneviniPrincipi2017" /><ref name="NestorRyanCook2010">{{cite journal | vauthors = Nestor MA, Ryan M, Cook AM | title = Catching the seizure culprit: drugs on the differential | journal = Orthopedics | volume = 33 | issue = 9 | pages = 679–682 | date = September 2010 | pmid = 20839747 | doi = 10.3928/01477447-20100722-16 | url = | quote = }}</ref><ref name="AtliDemir-OzkayIlgin2016">{{cite journal | vauthors = Atli O, Demir-Ozkay U, Ilgin S, Aydin TH, Akbulut EN, Sener E | title = Evidence for neurotoxicity associated with amoxicillin in juvenile rats | journal = Hum Exp Toxicol | volume = 35 | issue = 8 | pages = 866–876 | date = August 2016 | pmid = 26429924 | doi = 10.1177/0960327115607948 | bibcode = 2016HETox..35..866A | url = | quote = Till date, limited number of acute psychiatric adverse events (including seizure, encephalopathy, and tremor) related to AMX treatment have been reported in patients with no underlying psychiatric disorders.11–15 Furthermore, the Food and Drug Administration has published a report that when AMX was coadministered with cephalosporin, this combination therapy might cause death by inducing seizures in a patient.16}}</ref> Amoxicillin-induced [[neurotoxicity]] has been especially associated with concentrations of greater than 110{{nbsp}}mg/L.<ref name="LalanneBouzilléTron2023">{{cite journal | vauthors = Lalanne S, Bouzillé G, Tron C, Revest M, Polard E, Bellissant E, Verdier MC, Lemaitre F | title = Amoxicillin-Induced Neurotoxicity: Contribution of a Healthcare Data Warehouse to the Determination of a Toxic Concentration Threshold | journal = Antibiotics | volume = 12 | issue = 4 | date = March 2023 | page = 680 | pmid = 37107042 | pmc = 10135267 | doi = 10.3390/antibiotics12040680 | doi-access = free | url = }}</ref>


The onset of an [[allergic reaction]] to amoxicillin can be very sudden and intense; emergency medical attention must be sought as quickly as possible. The initial phase of such a reaction often starts with a change in mental state, skin rash with intense itching (often beginning in the fingertips and around the groin area and rapidly spreading), and sensations of fever, nausea, and vomiting. Any other symptoms that seem even remotely suspicious must be taken very seriously.  However, more mild allergy symptoms, such as a rash, can occur at any time during treatment, even up to a week after treatment has ceased.  For some people allergic to amoxicillin, the adverse effects can be fatal due to [[anaphylaxis]].<ref name="AHFS2015" />
The onset of an [[allergic reaction]] to amoxicillin can be very sudden and intense; emergency medical attention must be sought as quickly as possible. The initial phase of such a reaction often starts with a change in mental state, skin rash with intense itching (often beginning in the fingertips and around the groin area and rapidly spreading), and sensations of fever, nausea, and vomiting. Any other symptoms that seem even remotely suspicious must be taken very seriously.  However, more mild allergy symptoms, such as a rash, can occur at any time during treatment, even up to a week after treatment has ceased.  For some people allergic to amoxicillin, the adverse effects can be fatal due to [[anaphylaxis]].<ref name="AHFS2015" />
Line 168: Line 163:


===Nonallergic rash===
===Nonallergic rash===
Between 3 and 10% of children taking amoxicillin (or [[ampicillin]]) show a late-developing (>72 hours after beginning medication and having never taken penicillin-like medication previously) rash, which is sometimes referred to as the "amoxicillin rash". The rash can also occur in adults and may rarely be a component of the [[DRESS syndrome]].<ref>{{cite web |title=Amoxicillin Rash |url=https://hhma.org/healthadvisor/pa-ampirash-hhg/ |website=Tufts Medical Center |publisher=Tufts Medicine MelroseWakefield Hospital |access-date=24 June 2023 |archive-date=25 June 2023 |archive-url=https://web.archive.org/web/20230625145658/https://hhma.org/healthadvisor/pa-ampirash-hhg/ |url-status=dead }}</ref>
Between 3 and 10% of children taking amoxicillin (or [[ampicillin]]) show a late-developing (>72 hours after beginning medication and having never taken penicillin-like medication previously) rash, which is sometimes referred to as the "amoxicillin rash". The rash can also occur in adults and may rarely be a component of the [[DRESS syndrome]].<ref>{{cite web |title=Amoxicillin Rash |url=https://hhma.org/healthadvisor/pa-ampirash-hhg/ |website=Tufts Medical Center |publisher=Tufts Medicine MelroseWakefield Hospital |access-date=24 June 2023 |archive-date=25 June 2023 |archive-url=https://web.archive.org/web/20230625145658/https://hhma.org/healthadvisor/pa-ampirash-hhg/ }}</ref>


The rash is described as [[maculopapular]] or morbilliform ([[Measles|measles-like]]; therefore, in medical literature, it is called "amoxicillin-induced morbilliform rash".<ref>{{cite journal | vauthors = Barbaud AM, Béné MC, Schmutz JL, Ehlinger A, Weber M, Faure GC | title = Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes | journal = Archives of Dermatology | volume = 133 | issue = 4 | pages = 481–6 | date = April 1997 | pmid = 9126012 | doi = 10.1001/archderm.1997.03890400081011 | id = {{INIST|2654598}} }}</ref>). It starts on the trunk and can spread from there. This rash is unlikely to be a true allergic reaction and is not a contraindication for future amoxicillin usage, nor should the current regimen necessarily be stopped. However, this common amoxicillin rash and a dangerous allergic reaction cannot easily be distinguished by inexperienced persons, so a healthcare professional is often required to distinguish between the two.<ref>{{cite journal | vauthors = Pichichero ME | title = A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients | journal = Pediatrics | volume = 115 | issue = 4 | pages = 1048–57 | date = April 2005 | pmid = 15805383 | doi = 10.1542/peds.2004-1276 | s2cid = 21246804 }}</ref><ref>{{cite book | vauthors = Schmitt BD |title=Your child's health: the parents' one-stop reference guide to symptoms, emergencies, common illnesses, behavior problems, healthy development |edition=2nd |publisher=Bantam Books |location=New York |year=2005 |isbn=978-0-553-38369-0 |url-access=registration |url=https://archive.org/details/yourchildshealth00bart }}</ref>
The rash is described as [[maculopapular]] or morbilliform ([[Measles|measles-like]]; therefore, in medical literature, it is called "amoxicillin-induced morbilliform rash".<ref>{{cite journal | vauthors = Barbaud AM, Béné MC, Schmutz JL, Ehlinger A, Weber M, Faure GC | title = Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes | journal = Archives of Dermatology | volume = 133 | issue = 4 | pages = 481–6 | date = April 1997 | pmid = 9126012 | doi = 10.1001/archderm.1997.03890400081011 | id = {{INIST|2654598}} }}</ref>). It starts on the trunk and can spread from there. This rash is unlikely to be a true allergic reaction and is not a contraindication for future amoxicillin usage, nor should the current regimen necessarily be stopped. However, this common amoxicillin rash and a dangerous allergic reaction cannot easily be distinguished by inexperienced persons, so a healthcare professional is often required to distinguish between the two.<ref>{{cite journal | vauthors = Pichichero ME | title = A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients | journal = Pediatrics | volume = 115 | issue = 4 | pages = 1048–57 | date = April 2005 | pmid = 15805383 | doi = 10.1542/peds.2004-1276 | s2cid = 21246804 }}</ref><ref>{{cite book | vauthors = Schmitt BD |title=Your child's health: the parents' one-stop reference guide to symptoms, emergencies, common illnesses, behavior problems, healthy development |edition=2nd |publisher=Bantam Books |location=New York |year=2005 |isbn=978-0-553-38369-0 |url-access=registration |url=https://archive.org/details/yourchildshealth00bart }}</ref>
Line 182: Line 177:
== Interactions ==
== Interactions ==
Amoxicillin may interact with these drugs:
Amoxicillin may interact with these drugs:
* [[Anticoagulants]] ([[dabigatran]], [[warfarin]]).<ref name="Davisamox" /><ref name="bnf57">British National Formulary 57 March 2009</ref><ref name=":0" /><ref name=":1">{{Citation | vauthors = Reis W, Gaio J, Trang T, Reis H, Tang J, Juma H, Ramos F, Santos HD, Reis C |title=Antibiotics |date=2020 |url=https://doi.org/10.1007/978-981-15-3591-8_10 | veditors = Prabhakar H, Mahajan C, Kapoor I |work=Pharmacology in Clinical Neurosciences: A Quick Guide |pages=265–497 |access-date=9 April 2023 |place=Singapore |publisher=Springer |doi=10.1007/978-981-15-3591-8_10 |isbn=978-981-15-3591-8 |url-access=subscription }}</ref>
* [[Anticoagulants]] ([[dabigatran]], [[warfarin]]).<ref name="Davisamox" /><ref name="bnf57">British National Formulary 57 March 2009</ref><ref name=":0" /><ref name=":1">{{Citation | vauthors = Reis W, Gaio J, Trang T, Reis H, Tang J, Juma H, Ramos F, Santos HD, Reis C |title=Antibiotics |date=2020 | veditors = Prabhakar H, Mahajan C, Kapoor I |work=Pharmacology in Clinical Neurosciences: A Quick Guide |pages=265–497 |place=Singapore |publisher=Springer |doi=10.1007/978-981-15-3591-8_10 |isbn=978-981-15-3591-8 }}</ref>
* [[Methotrexate]] ([[chemotherapy]] and [[immunosuppressant]]).<ref name=":0" /><ref name=":1" />
* [[Methotrexate]] ([[chemotherapy]] and [[immunosuppressant]]).<ref name=":0" /><ref name=":1" />
* [[Typhoid vaccine|Typhoid]], [[Cholera vaccine|Cholera]] and [[BCG vaccine|BCG]] vaccines.<ref name=":0">{{cite book | vauthors = Arcangelo VP, Peterson AM, Wilbur V, Reinhold JA | date=17 August 2016 | publisher=LWW | title=Pharmacotherapeutics for Advanced Practice: A Practical Approach | url=https://books.google.com/books?id=FBJRDAAAQBAJ&pg=PT770 | isbn=978-1-496-31996-8}}</ref><ref name=":1" />
* [[Typhoid vaccine|Typhoid]], [[Cholera vaccine|Cholera]] and [[BCG vaccine|BCG]] vaccines.<ref name=":0">{{cite book | vauthors = Arcangelo VP, Peterson AM, Wilbur V, Reinhold JA | date=17 August 2016 | publisher=LWW | title=Pharmacotherapeutics for Advanced Practice: A Practical Approach | url=https://books.google.com/books?id=FBJRDAAAQBAJ&pg=PT770 | isbn=978-1-496-31996-8}}</ref><ref name=":1" />
Line 211: Line 206:
{{See also|Timeline of antibiotics}}
{{See also|Timeline of antibiotics}}


Amoxicillin was one of several [[semisynthesis|semisynthetic]] derivatives of 6-aminopenicillanic acid ([[6-APA]]) developed by the [[Beecham Group]] in the 1960s. It was invented by Anthony Alfred Walter Long and John Herbert Charles Nayler, two British scientists.<ref>{{cite patent |country=GB |number=978178 |status=patent |title=Penicillins |pubdate=1964-12-16 |fdate=1962-11-02 |pridate=1962-11-02 | inventor = Nayler JH, Smith H |assign1=Beecham Research Laboratories Ltd |url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=GB&NR=978178A&KC=A&FT=D&ND=&date=19641216&DB=&locale=en_EP}}</ref><ref>{{cite patent |country=GB |number=1241844 |status=patent |title=Penicillins |pubdate=1971-08-04 |fdate=1968-08-23 |pridate=1968-08-23 |inventor = Long AA, Nayler JH |assign1=Beecham Group LTD |url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=GB&NR=1241844&KC=&FT=E&locale=en_EP}}</ref> It became available in 1972 and was the second [[aminopenicillin]] to reach the market (after [[ampicillin]] in 1961).<ref>{{cite journal | vauthors = Geddes AM, Klugman KP, Rolinson GN | title = Introduction: historical perspective and development of amoxicillin/clavulanate | journal = International Journal of Antimicrobial Agents | volume = 30 | issue = Suppl 2 | pages = S109-12 | date = December 2007 | pmid = 17900874 | doi = 10.1016/j.ijantimicag.2007.07.015 }}</ref><ref name=Ravina>{{cite book | vauthors = Raviña E |title=The Evolution of Drug Discovery |publisher=Wiley-VCH |location=Weinheim |year=2014 |page=262 |isbn=978-3-527-32669-3}}</ref><ref>{{cite book | vauthors = Bruggink A |title=Synthesis of β-lactam antibiotics |publisher=Springer |year=2001 |page=17 |isbn=978-0-7923-7060-4}}</ref> [[Coamoxiclav|Co-amoxiclav]] became available in 1981.<ref name=Ravina/>
Amoxicillin was one of several [[semisynthesis|semisynthetic]] derivatives of 6-aminopenicillanic acid ([[6-APA]]) developed by the [[Beecham Group]] in the 1960s. It was invented by Anthony Alfred Walter Long and John Herbert Charles Nayler, two British scientists.<ref>{{cite patent |country=GB |number=978178 |status=patent |title=Penicillins |pubdate=1964-12-16 |fdate=1962-11-02 |pridate=1962-11-02 |inventor=Nayler JH, Smith H |assign1=Beecham Research Laboratories Ltd |url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=GB&NR=978178A&KC=A&FT=D&ND=&date=19641216&DB=&locale=en_EP }}{{Dead link|date=June 2025 |bot=InternetArchiveBot |fix-attempted=yes }}</ref><ref>{{cite patent |country=GB |number=1241844 |status=patent |title=Penicillins |pubdate=1971-08-04 |fdate=1968-08-23 |pridate=1968-08-23 |inventor=Long AA, Nayler JH |assign1=Beecham Group LTD |url=https://worldwide.espacenet.com/publicationDetails/biblio?CC=GB&NR=1241844&KC=&FT=E&locale=en_EP }}{{Dead link|date=June 2025 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> It became available in 1972 and was the second [[aminopenicillin]] to reach the market (after [[ampicillin]] in 1961).<ref>{{cite journal | vauthors = Geddes AM, Klugman KP, Rolinson GN | title = Introduction: historical perspective and development of amoxicillin/clavulanate | journal = International Journal of Antimicrobial Agents | volume = 30 | issue = Suppl 2 | pages = S109-12 | date = December 2007 | pmid = 17900874 | doi = 10.1016/j.ijantimicag.2007.07.015 }}</ref><ref name=Ravina>{{cite book | vauthors = Raviña E |title=The Evolution of Drug Discovery |publisher=Wiley-VCH |location=Weinheim |year=2014 |page=262 |isbn=978-3-527-32669-3}}</ref><ref>{{cite book | vauthors = Bruggink A |title=Synthesis of β-lactam antibiotics |publisher=Springer |year=2001 |page=17 |isbn=978-0-7923-7060-4}}</ref> [[Coamoxiclav|Co-amoxiclav]] became available in 1981.<ref name=Ravina/>


== Society and culture ==
== Society and culture ==
Line 220: Line 215:
Pharmaceutical manufacturers make amoxicillin in tri[[hydrate]] form, for oral use available as [[Capsule (pharmacy)|capsules]], regular, chewable and dispersible [[Tablet (pharmacy)|tablets]], syrup and [[pediatric]] [[Suspension (chemistry)|suspension]] for oral use, and as the sodium salt for [[intravenous]] administration.{{medical citation needed|date=September 2022}}
Pharmaceutical manufacturers make amoxicillin in tri[[hydrate]] form, for oral use available as [[Capsule (pharmacy)|capsules]], regular, chewable and dispersible [[Tablet (pharmacy)|tablets]], syrup and [[pediatric]] [[Suspension (chemistry)|suspension]] for oral use, and as the sodium salt for [[intravenous]] administration.{{medical citation needed|date=September 2022}}


An [[extended-release]] is available.<ref name="Moxatag FDA label" /><ref>{{cite web | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813_moxatag_toc.cfm | title=Drug Approval Package: Moxatag (amoxicillin extended-release) NDA #050813 | access-date=25 December 2018 | archive-date=3 December 2019 | archive-url=https://web.archive.org/web/20191203114048/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813_moxatag_toc.cfm | url-status=dead }}</ref> The intravenous form of amoxicillin is not sold in the United States.<ref>{{cite book| vauthors = Marek CL, Timmons SR |title=Pediatric Dentistry: Infancy Through Adolescence| veditors = Nowak A |date=2018|isbn=978-0-323-60826-8|publisher=[[Saunders (imprint)|Saunders]]}}</ref> When an intravenous aminopenicillin is required in the United States, ampicillin is typically used. When there is an adequate response to ampicillin, the course of antibiotic therapy may often be completed with oral amoxicillin.<ref>{{cite web|url=https://www.safetyandquality.gov.au/wp-content/uploads/2012/02/4.3-A-Quick-Guide-to-Switch_Southern-Health.pdf |archive-url=https://ghostarchive.org/archive/20221009/https://www.safetyandquality.gov.au/wp-content/uploads/2012/02/4.3-A-Quick-Guide-to-Switch_Southern-Health.pdf |archive-date=9 October 2022 |url-status=live|title=A Quick Guide to Switch : Antibiotics: IV to Oral|website=Safetyandquality.gov.au|access-date=1 March 2022}}</ref>
An [[extended-release]] is available.<ref name="Moxatag FDA label" /><ref>{{cite web | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813_moxatag_toc.cfm | title=Drug Approval Package: Moxatag (amoxicillin extended-release) NDA #050813 | access-date=25 December 2018 | archive-date=3 December 2019 | archive-url=https://web.archive.org/web/20191203114048/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813_moxatag_toc.cfm }}</ref> The intravenous form of amoxicillin is not sold in the United States.<ref>{{cite book| vauthors = Marek CL, Timmons SR |title=Pediatric Dentistry: Infancy Through Adolescence| veditors = Nowak A |date=2018|isbn=978-0-323-60826-8|publisher=[[Saunders (imprint)|Saunders]]}}</ref> When an intravenous aminopenicillin is required in the United States, ampicillin is typically used. When there is an adequate response to ampicillin, the course of antibiotic therapy may often be completed with oral amoxicillin.<ref>{{cite web|url=https://www.safetyandquality.gov.au/wp-content/uploads/2012/02/4.3-A-Quick-Guide-to-Switch_Southern-Health.pdf |archive-url=https://ghostarchive.org/archive/20221009/https://www.safetyandquality.gov.au/wp-content/uploads/2012/02/4.3-A-Quick-Guide-to-Switch_Southern-Health.pdf |archive-date=9 October 2022 |url-status=live|title=A Quick Guide to Switch: Antibiotics: IV to Oral|website=Safetyandquality.gov.au|access-date=1 March 2022}}</ref>


Research with mice indicated successful delivery using [[intraperitoneally]] injected amoxicillin-bearing [[microparticles]].<ref>{{cite journal | vauthors = Farazuddin M, Chauhan A, Khan RM, Owais M | title = Amoxicillin-bearing microparticles: potential in the treatment of Listeria monocytogenes infection in Swiss albino mice | journal = Bioscience Reports | volume = 31 | issue = 4 | pages = 265–72 | date = August 2011 | pmid = 20687896 | doi = 10.1042/BSR20100027 }}</ref>
Research with mice indicated successful delivery using [[intraperitoneally]] injected amoxicillin-bearing [[microparticles]].<ref>{{cite journal | vauthors = Farazuddin M, Chauhan A, Khan RM, Owais M | title = Amoxicillin-bearing microparticles: potential in the treatment of Listeria monocytogenes infection in Swiss albino mice | journal = Bioscience Reports | volume = 31 | issue = 4 | pages = 265–72 | date = August 2011 | pmid = 20687896 | doi = 10.1042/BSR20100027 }}</ref>
Line 226: Line 221:
===Names===
===Names===
<!-- DO NOT ADD DRUG NAMES HERE.  THERE ARE TOO MANY TO LIST IN WIKIPEDIA -->
<!-- DO NOT ADD DRUG NAMES HERE.  THERE ARE TOO MANY TO LIST IN WIKIPEDIA -->
Amoxicillin is the [[international nonproprietary name]] (INN),<ref>{{cite web |title=Amoxicillin [INN] |url=https://pubchem.ncbi.nlm.nih.gov/substance/134997708 |website=pubchem.ncbi.nlm.nih.gov |access-date=3 June 2024 }}</ref> [[British Approved Name]] (BAN), and [[United States Adopted Name]] (USAN), while amoxycillin is the [[Australian Approved Name]] (AAN).{{citation needed|date=September 2022}}
Amoxicillin is the [[international nonproprietary name]] (INN),<ref>{{cite web |title=Amoxicillin [INN] |url=https://pubchem.ncbi.nlm.nih.gov/substance/134997708 |website=pubchem.ncbi.nlm.nih.gov |access-date=3 June 2024 }}</ref> [[British Approved Name]] (BAN), [[Australian Approved Name]] (AAN), and [[United States Adopted Name]] (USAN), while amoxycillin is the former AAN.<ref>{{cite web|url=https://www.tga.gov.au/how-we-regulate/labelling-and-packaging/medicines-and-biologicals/labelling-requirements-international-harmonisation-ingredient-names-project/updating-medicine-ingredient-names-list-affected-ingredients|title=Updating medicine ingredient names - list of affected ingredients|date=5 April 2023|orig-date=23 November 2015|publisher=[[Therapeutic Goods Administration]]|accessdate=15 October 2025}}</ref>


Amoxicillin is one of the semisynthetic penicillins discovered by the former pharmaceutical company [[Beecham Group]]. The patent for amoxicillin has expired, thus amoxicillin and co-amoxiclav preparations are marketed under various brand names across the world.<ref name=brands>{{cite web|title=International brand names for amoxicillin|url=https://www.drugs.com/international/amoxicillin.html|website=Drugs.com|access-date=15 November 2016|url-status=deviated |archive-url=https://web.archive.org/web/20160529051432/http://www.drugs.com/international/amoxicillin.html|archive-date=29 May 2016}}</ref>
Amoxicillin is one of the semisynthetic penicillins discovered by the former pharmaceutical company [[Beecham Group]]. The patent for amoxicillin has expired, thus amoxicillin and co-amoxiclav preparations are marketed under various brand names across the world.<ref name=brands>{{cite web|title=International brand names for amoxicillin|url=https://www.drugs.com/international/amoxicillin.html|website=Drugs.com|access-date=15 November 2016|url-status=deviated |archive-url=https://web.archive.org/web/20160529051432/http://www.drugs.com/international/amoxicillin.html|archive-date=29 May 2016}}</ref>

Latest revision as of 14:14, 15 October 2025

Template:Short description Script error: No such module "Distinguish". Template:Use dmy dates Template:Cs1 config Template:Main other <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Template:Template otherScript error: No such module "TemplatePar".{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals=Script error: No such module "ParameterCount". | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=161935O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](c1ccc(O)cc1)N)[C@H]3SC2(C)C1S/C16H19N3O5S/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24)/t9-,10-,11+,14-/m1/s1LSQZJLSUYDQPKJ-NJBDSQKTSA-NTemplate:StdinchiciteTemplate:Stdinchicite1.6±0.1 [1] | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.coma685001Amoxicillin ABy mouth, intravenous (bolus), intramuscularAmoxil, Trimox, others[2]β-Lactam antibiotic; AminopenicillinJ01Template:ATCvet | _legal_data=S4Rx-only[3]POM[4][5][6][7]Rx-onlyRx-only

| _other_data=(2S,5R,6R)-6-{[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

| _image_0_or_2 = Amoxicillin skeletal formula labelled.svgAmoxicillin-from-xtal-3D-bs-17.png | _image_LR =

| _datapage = Amoxicillin (data page) | _vaccine_target=_type_not_vaccine | _legal_all=S4Rx-onlyPOMRx-onlyRx-only | _ATC_prefix_supplemental=J01Template:ATCvet | _has_EMA_link = | CAS_number=26787-78-0 | PubChem=33613 | ChemSpiderID=31006 | ChEBI=2676 | ChEMBL=1082 | DrugBank=DB01060 | KEGG=D07452 | _hasInChI_or_Key=yes | UNII=9EM05410Q9 | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs=Script error: No such module "ParameterCount". | _countIndexlabels=Script error: No such module "ParameterCount". | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields=changed |verifiedrevid=455343638}}

Amoxicillin is an antibiotic medication belonging to the aminopenicillin class of the penicillin family. The drug is used to treat bacterial infections[8] such as middle ear infection, strep throat, pneumonia, skin infections, odontogenic infections, and urinary tract infections.[8] It is taken orally (swallowed by mouth), or less commonly by either intramuscular injection or by an IV bolus injection, which is a relatively quick intravenous injection lasting from a couple of seconds to a few minutes.[8][9]

Common adverse effects include nausea and rash.[8] It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea.[10] It should not be used in those who are allergic to penicillin.[8] While usable in those with kidney problems, the dose may need to be decreased.[8] Its use in pregnancy and breastfeeding does not appear to be harmful.[8] Amoxicillin is in the β-lactam family of antibiotics.[8]

Amoxicillin was discovered in 1958 and came into medical use in 1972.[11][12] Amoxil was approved for medical use in the United States in 1974,[5][6] and in the United Kingdom in 1977.[3] It is on the World Health Organization's List of Essential Medicines.[13] It is one of the most commonly prescribed antibiotics in children.[14] Amoxicillin is available as a generic medication.[8] In 2023, it was the 23rd most commonly prescribed medication in the United States, with more than 23Template:Nbspmillion prescriptions.[15][16]

Medical uses

File:Amoxicillin.JPG
Amoxicillin BP

Amoxicillin is used in the treatment of a number of infections, including acute otitis media, streptococcal pharyngitis, pneumonia, skin infections, urinary tract infections, Salmonella infections, Lyme disease, and chlamydia infections.[8][17]

Acute otitis media

Children with acute otitis media who are younger than six months of age are generally treated with amoxicillin or other antibiotics. Although most children with acute otitis media who are older than two years old do not benefit from treatment with amoxicillin or other antibiotics, such treatment may be helpful in children younger than two years old with acute otitis media that is bilateral or accompanied by ear drainage.[18] In the past, amoxicillin was dosed three times daily when used to treat acute otitis media, which resulted in missed doses in routine ambulatory practice. There is now evidence that two-times daily dosing or once-daily dosing has similar effectiveness.[19]

Respiratory infections

Most sinusitis infections are caused by viruses, for which amoxicillin and amoxicillin-clavulanate are ineffective,[20] and the small benefit gained by amoxicillin may be overridden by the adverse effects.[21] Amoxicillin is considered the first-line empirical treatment for most cases of uncomplicated bacterial sinusitis in children and adults when culture data is unavailable.[22][23][24] Amoxicillin is recommended as the preferred first-line treatment for community-acquired pneumonia in adults by the National Institute for Health and Care Excellence, either alone (mild to moderate severity disease) or in combination with a macrolide.[25] Research suggests that is as effective as co-amoxiclav (a broad-spectrum antibiotic) for people admitted to hospital with pneumonia, regardless of its severity.[26][27] The World Health Organization (WHO) recommends amoxicillin as first-line treatment for pneumonia that is not "severe".[28] Amoxicillin is used in post-exposure inhalation of anthrax to prevent disease progression and for prophylaxis.[17]

H. pylori

It is effective as one part of a multi-drug regimen for the treatment of stomach infections of Helicobacter pylori. It is typically combined with a proton-pump inhibitor (such as omeprazole) and a macrolide antibiotic (such as clarithromycin); other drug combinations are also effective.[29] One old article suggests using amoxicillin with bismuth subsalicylate (pepto bismol) which does work.[30]

Lyme borreliosis

Amoxicillin is effective for the treatment of early cutaneous Lyme borreliosis; the effectiveness and safety of oral amoxicillin is neither better nor worse than common alternatively-used antibiotics.[31]

Odontogenic infections

Amoxicillin is used to treat odontogenic infections, infections of the tongue, lips, and other oral tissues. It may be prescribed following a tooth extraction, particularly in those with compromised immune systems.[32]

Skin infections

Amoxicillin is occasionally used for the treatment of skin infections,[17] such as acne vulgaris.[33] It is often an effective treatment for cases of acne vulgaris that have responded poorly to other antibiotics, such as doxycycline and minocycline.[34]

Infections in infants in resource-limited settings

Amoxicillin is recommended by the World Health Organization for the treatment of infants with signs and symptoms of pneumonia in resource-limited situations when the parents are unable or unwilling to accept hospitalization of the child. Amoxicillin in combination with gentamicin is recommended for the treatment of infants with signs of other severe infections when hospitalization is not an option.[35]

Prevention of bacterial endocarditis

It is also used to prevent bacterial endocarditis and as a pain-reliever in high-risk people having dental work done, to prevent Streptococcus pneumoniae and other encapsulated bacterial infections in those without spleens, people with damaged spleens (such as some with sickle-cell disease), and for both the prevention and the treatment of anthrax.[8] The United Kingdom recommends against its use for infectious endocarditis prophylaxis.[36] These recommendations do not appear to have changed the rates of infection for infectious endocarditis.[37]

Combination treatment

Script error: No such module "Labelled list hatnote".

Amoxicillin is susceptible to degradation by β-lactamase-producing bacteria, which are resistant to most β-lactam antibiotics, such as penicillin. For this reason, it may be combined with clavulanic acid, a β-lactamase inhibitor. This drug combination is commonly called co-amoxiclav.[38]

Spectrum of activity

It is a moderate-spectrum, bacteriolytic, β-lactam antibiotic in the aminopenicillin family used to treat susceptible Gram-positive and Gram-negative bacteria. It is usually the drug of choice within the class because it is better absorbed, following oral administration, than other β-lactam antibiotics. In general, Streptococcus, Bacillus subtilis, Enterococcus, Haemophilus, Helicobacter, and Moraxella are susceptible to amoxicillin, whereas Citrobacter, Klebsiella and Pseudomonas aeruginosa are resistant to it.[39] Some E. coli and most clinical strains of Staphylococcus aureus have developed resistance to amoxicillin to varying degrees.[40]

Adverse effects

Adverse effects are similar to those for other β-lactam antibiotics, including nausea, vomiting, rashes, and antibiotic-associated colitis. Diarrhea (loose bowel movements) may also occur.

Rarer adverse effects include mental and behavioral changes, lightheadedness, insomnia, hyperactivity, agitation, confusion, anxiety, sensitivity to lights and sounds, and unclear thinking.[4][41][42] Immediate medical care is required upon the first signs of these adverse effects.[8] Similarly to other penicillins, amoxicillin has been associated with an increased risk of seizures.[4][41][43][44] Amoxicillin-induced neurotoxicity has been especially associated with concentrations of greater than 110Template:Nbspmg/L.[45]

The onset of an allergic reaction to amoxicillin can be very sudden and intense; emergency medical attention must be sought as quickly as possible. The initial phase of such a reaction often starts with a change in mental state, skin rash with intense itching (often beginning in the fingertips and around the groin area and rapidly spreading), and sensations of fever, nausea, and vomiting. Any other symptoms that seem even remotely suspicious must be taken very seriously. However, more mild allergy symptoms, such as a rash, can occur at any time during treatment, even up to a week after treatment has ceased. For some people allergic to amoxicillin, the adverse effects can be fatal due to anaphylaxis.[8]

Use of the amoxicillin/clavulanic acid combination for more than one week has caused a drug-induced immunoallergic-type hepatitis in some patients. Young children having ingested acute overdoses of amoxicillin manifested lethargy, vomiting, and renal dysfunction.[46][47]

There is poor reporting of adverse effects of amoxicillin from clinical trials. For this reason, the severity and frequency of adverse effects from amoxicillin are probably higher than reported in clinical trials.[10]

Nonallergic rash

Between 3 and 10% of children taking amoxicillin (or ampicillin) show a late-developing (>72 hours after beginning medication and having never taken penicillin-like medication previously) rash, which is sometimes referred to as the "amoxicillin rash". The rash can also occur in adults and may rarely be a component of the DRESS syndrome.[48]

The rash is described as maculopapular or morbilliform (measles-like; therefore, in medical literature, it is called "amoxicillin-induced morbilliform rash".[49]). It starts on the trunk and can spread from there. This rash is unlikely to be a true allergic reaction and is not a contraindication for future amoxicillin usage, nor should the current regimen necessarily be stopped. However, this common amoxicillin rash and a dangerous allergic reaction cannot easily be distinguished by inexperienced persons, so a healthcare professional is often required to distinguish between the two.[50][51]

A nonallergic amoxicillin rash may also be an indicator of infectious mononucleosis. Some studies indicate about 80–90% of patients with acute Epstein–Barr virus infection treated with amoxicillin or ampicillin develop such a rash.[52]

Interactions

Amoxicillin may interact with these drugs:

When given intravenously or intramuscularly:[9]

  • It should not be mixed with blood products, or proteinaceous fluids (including protein hydrolysates) or with intravenous lipid emulsions
  • aminoglycoside should be injected at a separate site from amoxicillin if the patient is prescribed both medications at the same time. Neither drug should be mixed in a syringe. Neither should they be mixed in an intravenous fluid container or giving set because of loss of activity of the aminoglycoside under these conditions.
  • ciprofloxacin should not be mixed with amoxicillin.
  • Infusions containing dextran or bicarbonate should not be mixed with amoxicillin solutions.

Pharmacology

Amoxicillin (α-amino-p-hydroxybenzyl penicillin) is a semisynthetic derivative of penicillin with a structure similar to ampicillin but with better absorption when taken by mouth, thus yielding higher concentrations in blood and in urine.[58] Amoxicillin diffuses easily into tissues and body fluids. It will cross the placenta and is excreted into breastmilk in small quantities. It is metabolized by the liver and excreted into the urine. It has an onset of 30 minutes and a half-life of 3.7 hours in newborns and 1.4 hours in adults.[17]

Amoxicillin attaches to the cell wall of susceptible bacteria and results in their death. It is effective against streptococci, pneumococci, enterococci, Haemophilus influenzae, Escherichia coli, Proteus mirabilis, Neisseria meningitidis, Neisseria gonorrhoeae, Shigella, Chlamydia trachomatis, Salmonella, Borrelia burgdorferi, and Helicobacter pylori.[17] As a derivative of ampicillin, amoxicillin is a member of the penicillin family and, like penicillins, is a β-lactam antibiotic.[59] It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the bacterial cell wall. It has two ionizable groups in the physiological range (the amino group in alpha-position to the amide carbonyl group and the carboxyl group).[60]

Chemistry

Amoxicillin is a β-lactam and aminopenicillin antibiotic in terms of chemical structure.[61][62] It is structurally related to ampicillin.[61][62]

The experimental log P of amoxicillin is 0.87.[62][63] It is described as an "ambiphilic"—between hydrophilic and lipophilic—antibiotic.[64]

History

Script error: No such module "Labelled list hatnote".

Amoxicillin was one of several semisynthetic derivatives of 6-aminopenicillanic acid (6-APA) developed by the Beecham Group in the 1960s. It was invented by Anthony Alfred Walter Long and John Herbert Charles Nayler, two British scientists.[65][66] It became available in 1972 and was the second aminopenicillin to reach the market (after ampicillin in 1961).[67][68][69] Co-amoxiclav became available in 1981.[68]

Society and culture

Economics

Amoxicillin is relatively inexpensive.[70] In 2022, a survey of eight generic antibiotics commonly prescribed in the United States found their average cost to be about $42.67, while amoxicillin was sold for $12.14 on average.[71]

Modes of delivery

Pharmaceutical manufacturers make amoxicillin in trihydrate form, for oral use available as capsules, regular, chewable and dispersible tablets, syrup and pediatric suspension for oral use, and as the sodium salt for intravenous administration.Template:Medical citation needed

An extended-release is available.[7][72] The intravenous form of amoxicillin is not sold in the United States.[73] When an intravenous aminopenicillin is required in the United States, ampicillin is typically used. When there is an adequate response to ampicillin, the course of antibiotic therapy may often be completed with oral amoxicillin.[74]

Research with mice indicated successful delivery using intraperitoneally injected amoxicillin-bearing microparticles.[75]

Names

Amoxicillin is the international nonproprietary name (INN),[76] British Approved Name (BAN), Australian Approved Name (AAN), and United States Adopted Name (USAN), while amoxycillin is the former AAN.[77]

Amoxicillin is one of the semisynthetic penicillins discovered by the former pharmaceutical company Beecham Group. The patent for amoxicillin has expired, thus amoxicillin and co-amoxiclav preparations are marketed under various brand names across the world.[2]

Veterinary uses

Amoxicillin is also sometimes used as an antibiotic for animals. The use of amoxicillin for animals intended for human consumption (chickens, cattle, and swine for example) has been approved.[78]

References

Template:Reflist

Further reading

  • Script error: No such module "citation/CS1".

Template:PenicillinAntiBiotics Template:GlaxoSmithKline Script error: No such module "Navbox". Template:Portal bar Template:Authority control

  1. Script error: No such module "citation/CS1".
  2. a b Script error: No such module "citation/CS1".
  3. a b Script error: No such module "citation/CS1".
  4. a b c Script error: No such module "citation/CS1".
  5. a b Script error: No such module "citation/CS1".
  6. a b Script error: No such module "citation/CS1".
  7. a b Script error: No such module "citation/CS1".
  8. a b c d e f g h i j k l m Script error: No such module "citation/CS1".
  9. a b Script error: No such module "citation/CS1".
  10. a b Script error: No such module "Citation/CS1".
  11. Script error: No such module "citation/CS1".
  12. Script error: No such module "citation/CS1".
  13. Script error: No such module "citation/CS1".
  14. Script error: No such module "citation/CS1".
  15. Script error: No such module "citation/CS1".
  16. Script error: No such module "citation/CS1".
  17. a b c d e f Script error: No such module "citation/CS1".
  18. Script error: No such module "Citation/CS1".
  19. Script error: No such module "Citation/CS1".
  20. Script error: No such module "Citation/CS1".
  21. Script error: No such module "Citation/CS1".
  22. Script error: No such module "citation/CS1".
  23. Template:Cite Q
  24. Template:Cite Q
  25. Script error: No such module "citation/CS1".
  26. Script error: No such module "Citation/CS1".
  27. Script error: No such module "Citation/CS1".
  28. Script error: No such module "citation/CS1".
  29. Script error: No such module "Citation/CS1".
  30. Script error: No such module "Citation/CS1".
  31. Script error: No such module "Citation/CS1".
  32. Script error: No such module "Citation/CS1".
  33. Script error: No such module "citation/CS1".
  34. Script error: No such module "citation/CS1".
  35. Script error: No such module "citation/CS1".
  36. Script error: No such module "citation/CS1".
  37. Script error: No such module "Citation/CS1".
  38. Script error: No such module "citation/CS1".
  39. Script error: No such module "citation/CS1".
  40. Script error: No such module "Citation/CS1".
  41. a b Script error: No such module "Citation/CS1".
  42. Script error: No such module "Citation/CS1".
  43. Script error: No such module "Citation/CS1".
  44. Script error: No such module "Citation/CS1".
  45. Script error: No such module "Citation/CS1".
  46. Script error: No such module "Citation/CS1".
  47. Script error: No such module "citation/CS1".
  48. Script error: No such module "citation/CS1".
  49. Script error: No such module "Citation/CS1".
  50. Script error: No such module "Citation/CS1".
  51. Script error: No such module "citation/CS1".
  52. Script error: No such module "Citation/CS1".
  53. British National Formulary 57 March 2009
  54. a b c d e Script error: No such module "citation/CS1".
  55. a b c d e f Script error: No such module "citation/CS1".
  56. Script error: No such module "Citation/CS1".
  57. Script error: No such module "citation/CS1".
  58. Script error: No such module "Citation/CS1".
  59. Script error: No such module "citation/CS1".
  60. Script error: No such module "citation/CS1".
  61. a b Script error: No such module "Citation/CS1".
  62. a b c Script error: No such module "Citation/CS1".
  63. Script error: No such module "citation/CS1".
  64. Script error: No such module "Citation/CS1".
  65. Template:Cite patentTemplate:Dead link
  66. Template:Cite patentTemplate:Dead link
  67. Script error: No such module "Citation/CS1".
  68. a b Script error: No such module "citation/CS1".
  69. Script error: No such module "citation/CS1".
  70. Script error: No such module "citation/CS1".
  71. Script error: No such module "citation/CS1".
  72. Script error: No such module "citation/CS1".
  73. Script error: No such module "citation/CS1".
  74. Script error: No such module "citation/CS1".
  75. Script error: No such module "Citation/CS1".
  76. Script error: No such module "citation/CS1".
  77. Script error: No such module "citation/CS1".
  78. Script error: No such module "citation/CS1".